MDM2 amplification, P53 mutation, and accumulation of the P53 gene product in malignant fibrous histiocytoma

Diagnostic Molecular Pathology

Volumn 5, Issue 1, 1996, Pages 65-73

  Reid, Ann H ^a   Tsai, Mark M ^a   Venzon, David J ^b   Wright, Cynthia F ^a   Lack, E E ^b,c   O'Leary, Timothy J ^a,b  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amplification; MDM2; MFH; Mutation; P53

Indexed keywords

GENE PRODUCT;

ARTICLE; CANCER DIAGNOSIS; DERMATOFIBROMA; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; PATIENT SELECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

GENE AMPLIFICATION; GENE DELETION; GENES, P53; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; PROTO-ONCOGENES; SEQUENCE ANALYSIS, DNA; SOFT TISSUE NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030028076     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019606-199603000-00010     Document Type: Article

References (40)

1. Andreassen A, Oyjord T, Hovig E, et al. P53 abnormalities in different subtypes of human sarcomas. Cancer Res 1993; 53:468-71.
2. Barak Y, Juven T, Haffner R, Oren M. MDM2 expression is induced by wild-type p53 activity. EMBO J 1993;12:461-8.
3. Becker RL, Venzon D, Lack EE, Mikel UV, Weiss SW, O'Leary TJ. Cytometry and morphometry of malignant fibrous histiocytoma of the extremities: prediction of metastasis and mortality. Am J Surg Pathol 1991;15:957-64.
4. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of MDM2 and P53 genes in adult soft tissue sarcomas. Cancer Res 1994;54:794-9.
5. Costa J, Wesley RA, Glatstein E, Rosenberg SA. The grading of soft tissue sarcomas. Cancer 1984;53:530-41.
6. DiLella AG, Kwok SCM, Ledley FD, Marvit J, Woo SLC. Molecular structure and polymorphic map of the human phenylalanine hydroxylase gene. Biochemistry 1986;25:743-9.
7. Donehower LA, Bradley A. The tumor suppressor P53. Biochim Biophys Acta 1993;1155:181-205.
8. Drobnjak M, Latres E, Pollack D, et al. Prognostic implications of P53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. J Natl Cancer Inst 1994;86:549-54.
9. Dunn JM, Hastrich DJ, Newcomb P, Webb JCJ, Maitland NJ, Farndon JR. Correlation between p53 mutations and antibody staining in breast carcinoma. Br J Surg 1993;80: 1410-2.
10. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991;10: 1565-9.
11. Fine G, Ohorodnik JM, Horn RC. Soft tissue sarcomas: clinical behavior and course. In: Seventh National Cancer Conference Proceedings. Philadelphia: Lippincott, 1973:873-82.
12. Finlay CA. The MDM2 oncogene can overcome wild-type P53 suppression of transformed cell growth. Mol Cell Biol 1993;13:301-6.
13. Frye RA, Benz CC, Liu E. Detection of amplified oncogenes by differential polymerase chain reaction. Oncogene 1989; 4:1153-7.
14. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. Science 1991;253:49-53.
15. Hoppe-Seyler F, Butz K. Repression of endogenous P53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human MDM2, and mutant P53. J Virol 1993;67:3111-7.
16. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang WJ, Harris CC. Mutational hotspot in the P53 gene in human hepato-cellular carcinomas. Nature 1991;350:427-31.
17. Hsu SM, Raine L, Fanger H. Use of avidin-biotinperoxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
18. Hurlimann J, Chaubert P, Benhattar J. P53 gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques. Mod Pathol 1994;7:423-8.
19. Kawai A, Noguchi M, Beppu Y, et al. Nuclear immunoreaction of P53 protein in soft tissue sarcomas. A possible prognostic factor. Cancer 1994;73:2499-505.
20. Kihana T, Tsuda H, Teshima S, Okada S, Matsuuri S, Hirohashi S. High incidence of P53 gene mutation in human ovarian cancer and its association with nuclear accumulation of P53 protein and tumor DNA aneuploidy. Jpn J Cancer Res 1992;83:978-84.
21. Lack EE, Steinberg SM, White DE, Kinsella T, Gladstein E, Chang AE, Rosenberg SA. Extremity soft tissue sarcomas: analysis of prognostic variables in 300 cases and evaluation of tumor necrosis as a factor in stratifying higher-grade sarcomas. J Surg Oncol 1989;41:263-73.
22. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993;53:16-8.
23. Leach FS, Tokino T, Meltzer P, et al. P53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993;53:2231-4.
24. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The MDM2 oncogene product forms a complex with the P53 protein and inhibits P53-mediated transactivation. Cell 1992; 69:1237-45.
25. Mulligan LM, Matlashewski GJ, Scrable HJ, Cavenee WK. Mechanisms of P53 loss in human sarcomas. Proc Natl Acad Sci USA 1990;87:5863-9.
26. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a P53-associated protein in human sarcomas. Nature 1992;358:80-3.
27. Oliner JD, Pietenpol JA, Thiagalingum S, Gyuris J, Kinzler KW, Vogelstein B. MDM2 conceals the activation domain of tumor suppressor P53. Nature 1993;362:857-60.
28. Reid A, Thor A, Edgerton S, Tsai M, Wright C, O'Leary T. P53 accumulation and mutation are independent predictors of prognosis in node-positive breast cancer [Abstract 119]. Lab Invest 1995;72:24A.
29. Rosenberg SA, Kant H, Costa J, et al. Prospective randomized evaluation of the role of limb-sparing surgery, radiation therapy and adjuvant chemoimmunotherapy in the treatment of adult soft-tissue sarcomas. Surgery 1978;84:62-9.
30. Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft tissue sarcomas of the extremities. Prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982;196:305-15.
31. Rosenberg SA, Tepper J, Glatstein E, et al. Prospective evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities. Cancer 1983;52:424-34.
32. Rosenberg SA. Prospective randomized trials demonstrating the efficacy of adjuvant chemotherapy in adult patients with soft tissue sarcomas. Cancer Treat Rep 1984;68:1067-77.
33. Sommer SS, Cunningham J, McGovern RM, Saitoh S, Schroeder JJ, Wold LE, Kovach JS. Pattern of p53 gene mutations in breast cancers of women of the midwestern United States. J Natl Cancer Inst 1992;84:246-52.
34. Tepper J, Rosenberg SA, Glatstein E. Radiation therapy technique in soft tissue sarcomas of the extremity - policies of treatment at the National Cancer Institute. Int J Radiat Oncol Biol Phys 1982;8:263-73.
35. Thompson AM, Anderson TJ, Condie A, et al. p53 Allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int J Cancer 1992;50:528-32.
36. Thor A, Moore DH, Edgerton SM, et al. Accumulation of P53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84: 845-55.
37. Toguchida J, Yamaguchi T, Ritchie B, et al. Mutation spectrum of the P53 gene in bone and soft tissue sarcomas. Cancer Res 1992;52:6194-9.
38. Tsuda H, Hirohashi S. Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer. Int J Cancer 1994;57:498-503.
39. Weiss SW, Enziger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer 1978;41:2250-66.
40. Wright CF, Reid AH, Tsai MM, Ventre KM, Murari PJ, Frizzera G, O'Leary TJ. Detection of Epstein-Barr virus sequences in Hodgkin's disease by the polymerase chain reaction. Am J Pathol 1991;139:393-8.